rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone + Z + methotrexate

This is a multi-agent combination chemotherapy regimen composed of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, an unspecified agent "Z", and methotrexate. The core of this regimen closely resembles R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), which is a standard treatment for aggressive B-cell non-Hodgkin lymphomas such as diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMLBCL)[2][4]. Methotrexate is sometimes added to R-CHOP regimens for central nervous system prophylaxis or treatment in high-risk patients[1][3][5]. Each component has a distinct mechanism: - Rituximab is an anti-CD20 monoclonal antibody that targets B cells. - Cyclophosphamide is an alkylating agent causing DNA crosslinking. - Doxorubicin intercalates DNA and inhibits topoisomerase II. - Vincristine disrupts microtubule formation during mitosis. - Prednisone is a synthetic glucocorticoid with immunosuppressive effects. - Methotrexate inhibits dihydrofolate reductase interfering with DNA synthesis. The identity of "Z" in the regimen name could not be determined from available sources; it may represent either a placeholder or an error. This combination would be considered investigational unless "Z" can be clarified.